| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/05/2006 | WO2006044825A3 Mitotic kinesin inhibitors and methods of use thereof |
| 10/05/2006 | WO2006044045A3 Cryptosporidium hominis genes and gene products for chemotherapeutic, immunoprophylactic and diagnostic applications |
| 10/05/2006 | WO2006039073A3 Methods and compositions for reducing a level of a toxic protein in a cell |
| 10/05/2006 | WO2006036655A3 Use of low dose chemically modified tetracyclines to reduce inflammatory mediators |
| 10/05/2006 | WO2006034184A3 Use of modulators of a novel form of muscle selective calcineurin interacting protein (mcip-1-38) as a treatment for cardiovascular diseases |
| 10/05/2006 | WO2006033907A3 Methods of treating disorders having a component of mercury toxicity |
| 10/05/2006 | WO2006031977A3 Inhibition of pancreatic cancer cell growth |
| 10/05/2006 | WO2006026935A3 Pharmaceutical composition for rectal or vaginal application comprising a platinum complex |
| 10/05/2006 | WO2006026703A3 Chemical compounds |
| 10/05/2006 | WO2006020276A3 Antiviral compounds |
| 10/05/2006 | WO2006015124A3 Fused ring heterocycle kinase modulators |
| 10/05/2006 | WO2006014780A3 Methods and compositions for treating or preventing macular-degeneration related disorders |
| 10/05/2006 | WO2006014626A3 Partuculate constructs for release of active agents |
| 10/05/2006 | WO2006014219A3 Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral la-plus salts |
| 10/05/2006 | WO2006011050A3 Pyridine derivatives |
| 10/05/2006 | WO2006010078A3 Polymorphic form of naratriptan hydrochloride |
| 10/05/2006 | WO2006007496A3 Mitotic kinesin inhibitors |
| 10/05/2006 | WO2006004684A3 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
| 10/05/2006 | WO2005117561A3 Compositions and methods for diagnosing and treating diseases using low density lipoprotein-like lipid emulsions |
| 10/05/2006 | WO2005115392A8 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors |
| 10/05/2006 | WO2005110404A3 Compositions and methods for enhancing the effectiveness of a chemotherapeutic agent |
| 10/05/2006 | WO2005107702A3 Sustained release, mucoadhesive vaginal pharmaceutical compositions |
| 10/05/2006 | WO2005103050A3 Azaindoles useful as inhibitors of rock and other protein kinases |
| 10/05/2006 | WO2005102329A9 An innovative screening method for coronary heart disease and stroke |
| 10/05/2006 | WO2005092392A3 Conjugated psychotropic drugs and uses thereof |
| 10/05/2006 | WO2005091857A3 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders |
| 10/05/2006 | WO2005087265A8 Antineoplastic combinations of cci-779 and rituximab |
| 10/05/2006 | WO2005080338A8 New pharmaceutical compositions based on benzilic acid esters and soluble tnf receptor fusion proteins |
| 10/05/2006 | WO2005070081A3 Methods of using zonisamide as an adjunctive therapy for partial seizures |
| 10/05/2006 | WO2005065361A3 Compounds and compositions for treating dysproliferative diseases, and methods of use thereof |
| 10/05/2006 | WO2005062942A3 Novel oligonucleotides and treating cardiac disorders by using the same |
| 10/05/2006 | WO2005056837A3 Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
| 10/05/2006 | WO2005044244A3 Use of mrp4-inhibitors for the treatment and/or prophylaxis of cardiovascular diseases |
| 10/05/2006 | WO2005027837A3 Substituted sulfonamides |
| 10/05/2006 | WO2005020896A3 N,n-dihalogenated amino acids and derivatives |
| 10/05/2006 | WO2005013893A3 Cancer related genes |
| 10/05/2006 | WO2004108094A3 Sulfonamide-substituted chalcone derivatives and their use to treat diseases |
| 10/05/2006 | WO2004060308A3 Thiosemicarbazones as anti-virals and immunopotentiators |
| 10/05/2006 | WO2004044163A3 Methods for identifying risk of melanoma and treatments thereof |
| 10/05/2006 | WO2003106643A8 Novel polynucleotides encoding lamprey gnrh-iii |
| 10/05/2006 | US20060223990 Synthesis, deprotection, analysis & purification of RNA & ribozymes |
| 10/05/2006 | US20060223891 Use of alverine, alone or in combination with a tricyclic antidepressant or an antidepressant which is a specific inhibitor of serotonin reuptake for treatment of depression |
| 10/05/2006 | US20060223890 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
| 10/05/2006 | US20060223889 Veterinary aqueous injectable suspensions containing florfenicol |
| 10/05/2006 | US20060223888 Valproic acid analogues and pharmaceutical composition thereof |
| 10/05/2006 | US20060223887 Method for treating acute pancreatitis |
| 10/05/2006 | US20060223886 Derivatives of N-[heteroaryl(piperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics |
| 10/05/2006 | US20060223885 Derivatives of N-phenyl (piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics |
| 10/05/2006 | US20060223884 Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
| 10/05/2006 | US20060223883 Novel hydroxylated enantiomers of (-) 3a,6,6,9a-tetramethylperhydronaphtho[2,1-b]furan as perfuming agents derived from a fungal fermentation process. |
| 10/05/2006 | US20060223882 Amorphous simvastatin |
| 10/05/2006 | US20060223881 Use of gamma- tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease |
| 10/05/2006 | US20060223880 Methods of protecting against radiation injury |
| 10/05/2006 | US20060223879 Non-steroidal farnesoid x receptor modulators |
| 10/05/2006 | US20060223877 Methods of treatment utilizing certain melatonin derivatives |
| 10/05/2006 | US20060223876 Indoloquinone Tumor Radiation Sensitization |
| 10/05/2006 | US20060223875 Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes |
| 10/05/2006 | US20060223874 Heterocyclic reverse transcriptase inhibitors |
| 10/05/2006 | US20060223873 Isoxazole derivatives and methods of treating nitric oxide mediated diseases |
| 10/05/2006 | US20060223871 Thiophene-and thiazolesulfonamides as antineoplastic agents |
| 10/05/2006 | US20060223870 Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
| 10/05/2006 | US20060223869 Dopamine D1, D2, D3, and D4 receptor agonist such as pramipexole in combination with a second active substance selected from D1, D2, D3, and D4 receptor agonists, anorectics, lipase inhibitors and sympathomimetics; for treating overweight or obesity or type 2 diabetes |
| 10/05/2006 | US20060223868 Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) |
| 10/05/2006 | US20060223867 administering two or more timed doses of 7,11-Dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methylsulfanyl-thiazol-4-yl)-vinyl]-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione also called epothilone b; treating a drug resistant tumor; ovarian cancer |
| 10/05/2006 | US20060223866 Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
| 10/05/2006 | US20060223865 Therapeutic combination |
| 10/05/2006 | US20060223864 Thiadiazoles AS CXC- and CC- chemokine receptor ligands |
| 10/05/2006 | US20060223863 Methods for treating Hepatitis C |
| 10/05/2006 | US20060223862 administration of catalytic iron chelator compound, then urine screening for creatinine levels |
| 10/05/2006 | US20060223860 e.g. 3-(4-{[6-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethyl}amino)-hexyl]oxy}butyl)benzenesulfonamide; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity; bronchodilator agent; pulmonary disorders: chronic obstructive pulmonary dusease; asthma |
| 10/05/2006 | US20060223859 Chronic obstructive pulmonary dusease; asthma |
| 10/05/2006 | US20060223858 Chronic obstructive pulmonary dusease; asthma |
| 10/05/2006 | US20060223857 Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression |
| 10/05/2006 | US20060223856 Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors |
| 10/05/2006 | US20060223855 reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity |
| 10/05/2006 | US20060223854 For therapy of thromboembolic and/or inflammatory disorders |
| 10/05/2006 | US20060223853 e.g. 1-[2-hydroxy-3-(quinolin-5-yloxy)-propyl]-piperidine-4-carboxylic acid [4-phenyl-1-(3-phenyl-propyl)-butyl]-amide; multidrug resistance protein or P-glycoprotein modulator; with other therapeutic agent: anticarcinogenic, antibacterial, antiviral, antifungal agents |
| 10/05/2006 | US20060223852 (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome |
| 10/05/2006 | US20060223851 Triamide-substituted heterobicyclic compounds |
| 10/05/2006 | US20060223850 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors |
| 10/05/2006 | US20060223849 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors |
| 10/05/2006 | US20060223848 Caspase inhibitors containing isoxazoline ring |
| 10/05/2006 | US20060223847 Anti-coronavirus drug |
| 10/05/2006 | US20060223846 Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
| 10/05/2006 | US20060223845 Clopidogrel base suitable for pharmaceutical formulation and preparation thereof |
| 10/05/2006 | US20060223844 Mitotic kinesin inhibitors |
| 10/05/2006 | US20060223843 Substituted 1,5-naphthyridine azolinones |
| 10/05/2006 | US20060223842 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia |
| 10/05/2006 | US20060223841 Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine |
| 10/05/2006 | US20060223840 Substituted piperidine compounds and methods of their use |
| 10/05/2006 | US20060223839 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds |
| 10/05/2006 | US20060223838 Methods and compositions for the treatment of hyperlipidemia |
| 10/05/2006 | US20060223837 Biaryl derived amide modulators of vanilloid VR1 receptor |
| 10/05/2006 | US20060223836 New phenylalanine derivatives |
| 10/05/2006 | US20060223835 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation |
| 10/05/2006 | US20060223834 Diketo acids on nucleobase scaffolds as inhibitors of Flaviviridae |
| 10/05/2006 | US20060223833 inhibitors of polo-like kinases; (4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-[3-ethyl-4-oxo-5-[1-[3-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetonitrile; cancer, auto-immune diseases, cardiovascular diseases |
| 10/05/2006 | US20060223832 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| 10/05/2006 | US20060223831 Bromide and its crystal |
| 10/05/2006 | US20060223830 Serotonin reuptake inhibitor and/or NeuroKinin 1 antagonist; 1-[(1RS)-1-(3,5-dibromobenzyloxymethyl)indan-1-yl]piperazine; depression; anxiety; nausea and gastrointestinal disorders; dementias; inflammation; pain; stress etc. |